A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines

Biological Procedures Online

Volumn 14, Issue 1, 2012, Pages

  Hesson, Luke B ^a   Packham, Deborah ^a   Pontzer, Emily ^b,c   Funchain, Pauline ^b   Eng, Charis ^b,c   Ward, Robyn L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cowden syndrome; Dna methylation; Epigenetic; Killin; Pseudogene; PTEN; PTENP1

Indexed keywords

DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; BREAST CANCER; CANCER CELL LINE; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LUNG CANCER; OVARY CANCER; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN METHYLATION; PSEUDOGENE; PTEN GENE; PTENP1 GENE; PYROSEQUENCING; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE;

EID: 84920694497     PISSN: None     EISSN: 14809222     Source Type: Journal    
DOI: 10.1186/1480-9222-14-5     Document Type: Article

References (21)

1. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
2. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998, 95:15587-15591.
3. Hollander MC, Blumenthal GM, Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011, 11:289-301.
4. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboue B, Lin AY, et al: Mutation spectrum and genotypephenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998, 7:507-515.
5. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA, Stratton MR: Cosmic 2005. Br J Cancer 2006, 94:318-322.
6. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, et al: MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997, 57:5221-5225.
7. Dahia PL, Fitz Gerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von Deimling A, Haluska FG, Haber DA, Eng C: A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene 1998, 16:2403-2406.
8. Fujii GH, Morimoto AM, Berson AE, Bolen JB: Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN. Oncogene 1999, 18:1765-1769.
9. Yokoyama Y, Wan X, Shinohara A, Takahashi S, Takahashi Y, Niwa K, Tamaya T: Expression of PTEN and PTEN pseudogene in endometrial carcinoma. Int J Mol Med 2000, 6:47-50.
10. Zhang CL, Tada M, Kobayashi H, Nozaki M, Moriuchi T, Abe H: Detection of PTEN nonsense mutation and psiPTEN expression in central nervous system high-grade astrocytic tumors by a yeast-based stop codon assay. Oncogene 2000, 19:4346-4353.
11. Ioffe YJ, Chiappinelli KB, Mutch DG, Zighelboim I, Goodfellow PJ: Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis? Gynecol Oncol 2012, 124(2):340-346.
12. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, Kelsey KT: PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005, 36:768-776.
13. Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H: PTEN methylation and expression in glioblastomas. Acta Neuropathol 2003, 106:479-485.
14. Liu J, Kagan J: Method to distinguish between the MMAC1/PTEN gene and its pseudogene in RT-PCR analysis of point mutations. Biotechniques 1999, 26:19-22, 24.
15. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, Hengge UR: Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006, 66:6546-6552.
16. Bennett KL, Mester J, Eng C: Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA 2010, 304:2724-2731.
17. Bennett KL, Campbell R, Ganapathi S, Zhou M, Rini B, Ganapathi R, Neumann HP, Eng C: Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes Cancer 2011, 50:654-661.
18. Cho YJ, Liang P: Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc Natl Acad Sci USA 2008, 105:5396-5401.
19. Whang YE, Wu X, Sawyers CL: Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. J Natl Cancer Inst 1998, 90:859-861.
20. Zysman MA, Chapman WB, Bapat B: Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 2002, 160:795-800.
21. Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997, 25:2532-2534.